BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10746555)

  • 1. Frequency of human leukocyte antigen-A 24 alleles in patients with melanoma determined by human leukocyte antigen-A sequence-based typing.
    Bettinotti MP; Norris RD; Hackett JA; Thompson CO; Simonis TB; Stroncek D; Marincola FM
    J Immunother; 2000; 23(2):282-7. PubMed ID: 10746555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes.
    Kang X; Kawakami Y; el-Gamil M; Wang R; Sakaguchi K; Yannelli JR; Appella E; Rosenberg SA; Robbins PF
    J Immunol; 1995 Aug; 155(3):1343-8. PubMed ID: 7543520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma.
    Kawakami Y; Dang N; Wang X; Tupesis J; Robbins PF; Wang RF; Wunderlich JR; Yannelli JR; Rosenberg SA
    J Immunother; 2000 Jan; 23(1):17-27. PubMed ID: 10687134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
    Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
    J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunodominance across HLA polymorphism: implications for cancer immunotherapy.
    Kim CJ; Parkinson DR; Marincola F
    J Immunother; 1998 Jan; 21(1):1-16. PubMed ID: 9456431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase.
    Riley JP; Rosenberg SA; Parkhurst MR
    J Immunother; 2001; 24(3):212-20. PubMed ID: 11394498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.
    Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M
    Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy.
    Robbins PF; el-Gamil M; Kawakami Y; Stevens E; Yannelli JR; Rosenberg SA
    Cancer Res; 1994 Jun; 54(12):3124-6. PubMed ID: 8205528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail.
    Akiyama Y; Maruyama K; Nara N; Mochizuki T; Yamamoto A; Yamazaki N; Kawashima I; Nukaya I; Takesako K; Yamaguchi K
    Anticancer Res; 2004; 24(2B):571-7. PubMed ID: 15160996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in frequency distribution of HLA-A2 subtypes between North American and Italian white melanoma patients: relevance for epitope specific vaccination protocols.
    Player MA; Barracchini KC; Simonis TB; Rivoltini L; Arienti F; Castelli C; Mazzocchi A; Belli F; Parmiani G; Marincola FM
    J Immunother Emphasis Tumor Immunol; 1996 Sep; 19(5):357-63. PubMed ID: 8941875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
    Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
    Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete subtyping of the HLA-A locus by sequence-specific amplification followed by direct sequencing or single-strand conformation polymorphism analysis.
    Blasczyk R; Hahn U; Wehling J; Huhn D; Salama A
    Tissue Antigens; 1995 Aug; 46(2):86-95. PubMed ID: 7482512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo.
    Drexler I; Antunes E; Schmitz M; Wölfel T; Huber C; Erfle V; Rieber P; Theobald M; Sutter G
    Cancer Res; 1999 Oct; 59(19):4955-63. PubMed ID: 10519409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A MAGE-1-encoded HLA-A24-binding synthetic peptide induces specific anti-tumor cytotoxic T lymphocytes.
    Fujie T; Tahara K; Tanaka F; Mori M; Takesako K; Akiyoshi T
    Int J Cancer; 1999 Jan; 80(2):169-72. PubMed ID: 9935194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis.
    Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC
    J Immunol Methods; 2000 Oct; 244(1-2):59-67. PubMed ID: 11033019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage.
    Lupetti R; Pisarra P; Verrecchia A; Farina C; Nicolini G; Anichini A; Bordignon C; Sensi M; Parmiani G; Traversari C
    J Exp Med; 1998 Sep; 188(6):1005-16. PubMed ID: 9743519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promiscuous CTL recognition of viral epitopes on multiple human leukocyte antigens: biological validation of the proposed HLA A24 supertype.
    Burrows SR; Elkington RA; Miles JJ; Green KJ; Walker S; Haryana SM; Moss DJ; Dunckley H; Burrows JM; Khanna R
    J Immunol; 2003 Aug; 171(3):1407-12. PubMed ID: 12874232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes.
    Topalian SL; Gonzales MI; Parkhurst M; Li YF; Southwood S; Sette A; Rosenberg SA; Robbins PF
    J Exp Med; 1996 May; 183(5):1965-71. PubMed ID: 8642306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluorescein-labeled synthetic peptides.
    Kessler JH; Mommaas B; Mutis T; Huijbers I; Vissers D; Benckhuijsen WE; Schreuder GM; Offringa R; Goulmy E; Melief CJ; van der Burg SH; Drijfhout JW
    Hum Immunol; 2003 Feb; 64(2):245-55. PubMed ID: 12559627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequencing of two HLA-A blank alleles: implications in unrelated bone marrow donor matching.
    Zanone-Ramseier R; Gratwohl A; Gmür J; Roosnek E; Tiercy JM
    Transplantation; 1999 May; 67(10):1336-41. PubMed ID: 10360587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.